Vertex Pharmaceuticals (VRTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX)

VRTX 454.67

-1.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	10/3/2005 6:46:33 PM
	Read Replies (1) of 1169

<<Clinical Update Vertex affirmed today that it remains on track to achieve key milestones in its VX-950 clinical program in the fourth quarter of 2005, including initiation of a 14-day Phase Ib combination study of VX-950 and pegylated interferon in Europe and filing of an investigational new drug (IND) application in the United States to support Phase II development of VX-950. Vertex anticipates that it will initiate a 28-day, Phase II combination study of VX-950 and pegylated interferon by year-end. Vertex expects to present additional VX-950 clinical data at two more medical conferences in the fourth quarter of 2005.>> PIb ...14 days PII ...28 days PIIb.....XX days PIII...who knows???? I guss, market think this is for real? Maybe, but I am far from believer. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next